Madurai News

Non-Cystic Fibrosis Bronchiectasis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, InsMed, Zambon, Chiesi Farmaceutici and Many Others

 Breaking News
  • No posts were found

Non-Cystic Fibrosis Bronchiectasis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, InsMed, Zambon, Chiesi Farmaceutici and Many Others

July 23
16:46 2021
Non-Cystic Fibrosis Bronchiectasis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novartis, InsMed, Zambon, Chiesi Farmaceutici and Many Others

Non-Cystic Fibrosis Bronchiectasis Pipeline

Non-cystic Fibrosis Bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by permanent retention of mucus, dilation of bronchi, and ciliary clearance impairment. Some Clinical features include chronic daily cough, shortness of breath, sputum, and recurrent respiratory infections, with increased morbidity and worsened quality of life. One of the keystones in management of bronchiectasis is the identification & treatment of underlying causes.

 

DelveInsight’s Non-cystic Fibrosis Bronchiectasis Pipeline Insights report offers exhaustive coverage of the emerging therapies in different stages of development from preclinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. 

 

Some of the important takeaways from the Non-cystic Fibrosis Bronchiectasis Pipeline report:

  • NCFB Pipeline report offers an extensive analysis of 5+ key players and 5+ key therapies.
  • Non-cystic Fibrosis Bronchiectasis pipeline candidates are under evaluation in different stages of the clinical phase, such as CHF 6333, Brensocatib, and others expected to get launched in the foreseeable future.
  • Some of the key companies expanding the Non-cystic Fibrosis Bronchiectasis Pipeline are Chiesi Farmaceutici, AstraZeneca, and Insmed.
  • In September 2020, US biotech Insmed trumpeted updated phase 2 data from its brensocatib at this week’s virtual European Respiratory Society conference. It showed the drug prolonged time to exacerbations caused by the rare lung disease known as non-cystic fibrosis bronchiectasis (NCFBE).

 

Request for Sample Page: https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

NCFB Symptoms:

The symptoms & clinical course of non-cystic fibrosis bronchiectasis are variable. Some of the patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily.

 

Non-cystic Fibrosis Bronchiectasis Causes

The most common cause of NCFB in the literature is post-infectious. This is not a well-defined entity, but the usual context appears to be one acute infectious episode that is thought to result in bronchiectasis. A possible mechanism for post-infectious NCFB is a significant infection in early childhood which causes structural damage to the developing lung, allowing perpetual bacterial infection. Over time, the persistent infection may then result in bronchiectasis.

 

Request for Sample Page: https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

Non-cystic Fibrosis Bronchiectasis Companies are:

  • Santhera Pharmaceuticals
  • Novartis
  • InsMed
  • Zambon
  • Chiesi Farmaceutici
  • And Many Others

 

DelveInsight’s NCFB Report covers around 5+ products under different phases of clinical development like:

  • Late-stage products (Phase III)
  • Discontinued & Inactive candidates
  • Mid-stage products (Phase II)
  • Route of Administration
  • Early-stage product along with the details of Pre-clinical and Discovery stage candidates

 

Request for Sample Page: https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

Non-cystic Fibrosis Bronchiectasis Therapies are:

  • Lonodelestat
  • Tobramycin dry-powder inhalation
  • INS-1007
  • Colistimethate sodium
  • CHF 6333
  • And Many Others

 

Scope of the Non-Cystic Fibrosis Bronchiectasis Pipeline Report

Coverage: Global

 Key Players: Santhera Pharmaceuticals, Novartis, InsMed, Zambon, Chiesi Farmaceutici, among others.

 Key Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies: Lonodelestat, Tobramycin dry-powder inhalation, INS-1007, Colistimethate sodium, CHF 6333, and others.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

Categories